Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Vivacit-E Post-market Follow-up Study

A legfontosabb adatok

Ki végzi
Zimmer Biomet
Hol
Austin, Chapel Hill, Charlotte, Parker és Philadelphia (Egyesült Államok)Mind a 5 helyszín megnézése
Azonosító
Állapot
Befejeződött
Résztvevők
245 fő vett részt
Kezdés
2013. okt. 1.
Befejezés
2026. ápr. 14.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Vivacit-E Liner
A regiszteradat frissítve
2026. szeptember 4.

Ki vehet részt

Életkor
18 év – 60 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 17 feltétel megnézéseKevesebb

Ki vehet részt

  • Patient is 18 to 60 years of age, inclusive
  • Patient is skeletally mature
  • Patient qualifies for primary unilateral or bilateral total hip arthroplasty (THA) based on physical exam and medical history including at least one of the following:
  • Osteoarthritis
  • Avascular necrosis (AVN)
  • Post-traumatic arthritis
  • Congenital hip dysplasia
  • Patient has no history of previous total hip replacement or arthrodesis of the affected hip joint(s)
  • Patient is willing and able to provide written informed consent
  • Patient is willing and able to cooperate in the required post-operative therapy
  • Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent
  • Patient has participated in the Informed Consent process and has signed the IRB/EC approved informed consent

Ki nem vehet részt

  • The patient is:; a prisoner mentally incompetent or unable to understand what participation in the study entails a known alcohol or drug abuser; anticipated to be non-compliant; The patient has an acute, chronic, or systemic infection(s); The patient has total or partial absence of the muscular or ligamentous apparatus; The patient has neuromuscular compromise, vascular deficiency or other conditions in the affected limb that may lead to inadequate skeletal fixation; The patient has osteoradionecrosis; The patient has lack of bony structures proximal or distal to the operative joint, so that good implant fixation is unlikely or impossible; The patient has local bone tumors/cysts in the bone to be retained that the implanting surgeon determines could inhibit implant fixation; The patient is skeletally immature; The patient has any concomitant disease that can jeopardize the functioning and the success of the implant; The patient is known to be pregnant; The patient has a known sensitivity or allergic reaction to one or more of the implanted materials which include metal (titanium, tivanium, tantalum, cobalt, chromium, nickel) and ceramic
  • Patient is unwilling or unable to give consent or to comply with the follow-up program
  • Patient has a total prosthetic hip replacement device (including surface replacement arthroplasty, endoprosthesis, etc. in the affected hip joint(s)
  • Inflammatory Arthritis
  • Rheumatoid Arthritis

Helyszínek itt: Egyesült Államok

  • Texas Institute for Hip and Knee SurgeryAustin, Egyesült Államok
  • Department of Orthopaedics University of North Carolina at Chapel HillChapel Hill, Egyesült Államok
  • OrthoCarolina Research InstituteCharlotte, Egyesült Államok
  • Denver Hip and Knee, Inc.Parker, Egyesült Államok
  • Rothman InstitutePhiladelphia, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The objectives of this study are to obtain clinical performance (outcomes) data and survivorship for commercially available Vivacit-E (HXPE) liners. This will be done by analysis of polyethylene wear, validated outcome measurement tools, radiographs, and reported adverse events data.

A vizsgálat csoportja

  • Vivacit-E LinerEgyéb csoport

    All subjects enrolled receive the study implant.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Post Market Clinical Follow-up Study of the Zimmer Vivacit-E Highly Crosslinked Polyethylene Liner Used With the Continuum Acetabular Shell
A regiszteradat frissítve
2026. szeptember 4.